

Thomas Beimers

Partner

Minneapolis

Washington, D.C.

Biography

Health care and life sciences industry clients with challenging regulatory compliance problems, especially False Claims Act (FCA) investigations, turn to Tom Beimers. Tom's service with the Department of Health and Human Services Office of Inspector General (HHS OIG), combined with extensive private practice litigation and investigations experience, helps clients navigate all phases of complex regulatory matters.

Sometimes FCA cases settle, and when they do Tom's experience with the HHS OIG Corporate Integrity Agreement (CIA) process, including negotiating and monitoring CIAs, ensures that clients negotiate and address implementation issues from a position of strength.

Tom enjoys advising health care and life sciences clients on regulatory compliance and health care fraud and abuse matters. He regularly provides strategic analysis regarding business arrangements and proposed transactions, including customer contracts, discount and rebate arrangements, business courtesies, consulting agreements, marketing programs, aggregate spend reporting, and charitable programs. Tom's experience with OIG and as an advisor to multiple life sciences and health care companies allows him to benchmark against industry standard practices and agency perspectives. This broad vantage point helps



Phone

+1 202 637 5600 (Washington, D.C.)

Fax

+1 612 402 3001 (Minneapolis)

+1 202 637 5910 (Washington, D.C.)

Email

thomas.beimers@hoganlovells.com

Languages

English

Practices

Health

Medical Device and Technology
Regulatory

Pharmaceuticals and Biotechnology
Regulatory

Investigations, White Collar, and
Fraud

Industries

Life Sciences and Health Care

ensure that clients are simultaneously able to meet legal requirements and engage in competitive business arrangements.

Tom had a distinguished career in government before joining his previous international law firm. He served as senior counsel for HHS OIG, where he helped resolve major FCA cases involving off-label marketing, drug pricing, Anti-Kickback Statute violations, and Medicaid and Medicare reimbursement, and served as a monitor for manufacturers operating under CIAs. He was also a Special Assistant U.S. Attorney, serving as a prosecutor for the Department of Justice's Medicare Fraud Strike Force in Detroit, Michigan. In that role, he oversaw all phases of investigations into violations of criminal health care fraud laws, including jury trials.

Tom is a frequent national speaker and author on topics related to health care fraud and abuse, white collar criminal defense, and compliance matters.

Representative experience

Acts as lead defense counsel on False Claims Act matters involving allegations of Anti-Kickback Statute violations in medical device industry.

Routinely handles internal investigations involving matters such as off-label promotion, drug pricing, and Medicare and Medicaid reimbursement issues.

Served as interim compliance officer for global medical device manufacturer.

Has assisted clients with implementation of aggregate spend reporting required under CMS Open Payments Law (Physician Payments Sunshine Act).

Served as OIG monitor for several pharmaceutical industry Corporate Integrity Agreements.

Former prosecutor with joint DOJ/HHS Medicare Fraud Strike Force.

Awards and rankings

■ Healthcare: Health Insurers, *Legal 500 US*, 2017

Areas of focus

False Claims Act and Qui Tam

Education and admissions

Education

J.D., University of Minnesota Law School, magna cum laude, 1998

B.A., Macalester College, Phi Beta Kappa, 1991

Bar admissions and qualifications

Minnesota

District of Columbia

Court admissions

U.S. Supreme Court

U.S. Court of Appeals, District of Columbia Circuit

U.S. Court of Appeals, Eighth Circuit

U.S. Court of Appeals, Fifth Circuit

U.S. Court of Appeals, Fourth Circuit

U.S. Court of Appeals, Ninth Circuit

- Healthcare: Service Providers, *Legal 500 US*, 2017

Latest thinking and events

- News
 - OIG green lights drug manufacturer-sponsored genetic testing program
- News
 - PhRMA responds: Code on Interactions with HCPs updated following fraud alert on speaker programs
- Hogan Lovells Publications
 - Health care trends in a post-pandemic economy
Life Sciences & Health Care Alert
- News
 - Time's up: New enforcement era for regenerative medicines begins June 1
- News
 - Ramping up the drug pricing debate: Dueling bills and paying for health care infrastructure
- News
 - HHS Regulatory Sprint takes final shape, Part 2: AKS, Stark regulatory revisions for value-based care